X4 Pharmaceuticals, Inc. (XFOR) Q1 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for X4 Pharmaceuticals, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.069 -- 00:00:01.851 first quarter 2024 00:00:01.851 -- 00:00:07.476 earnings conference call. At this time, all participants are in a listen-only mode. 00:00:07.476 -- 00:00:11.180 A question and answer session will follow the formal presentation. 00:00:11.180 -- 00:00:14.363 As a reminder, this conference is being recorded. 00:00:14.363 -- 00:00:17.606 It is now my pleasure to introduce your host, Mr. 00:00:17.606 -- 00:00:20.929 Dan Ferry from LifeSci Advisors. Thank you, Mr. 00:00:20.929 -- 00:00:21.489 Ferry. 00:00:21.489 -- 00:00:23.810 You may begin. 00:00:29.875 -- 00:00:32.676 Thank you, Operator, and good morning, everyone. 00:00:32.676 -- 00:00:34.937 Thank you for joining us today. 00:00:34.937 -- 00:00:40.019 Presenting on today's call will be Dr. Paula Regan, X4's President and CEO, and the 00:00:40.019 -- 00:00:43.940 company's Chief Financial Officer, Adam Mostafa. 00:00:43.940 -- 00:00:47.802 Following prepared remarks, we will open up the call to your questions 00:00:47.802 -- 00:00:52.704 and will be joined by Chief Commercial Officer, Mark Baldry, Chief Medical Officer, Dr. 00:00:52.704 -- 00:00:55.065 Christoph Arbett-Engels, 00:00:55.065 -- 00:00:58.877 Chief Operating Officer, Dr. Mary Bibiasi, 00:00:58.877 -- 00:01:03.900 Chief Scientific Officer, Dr. Art Tavares, and Jose Juves, 00:01:03.900 -- 00:01:06.921 Head of Corporate and Patient Affairs. 00:01:06.921 -- 00:01:11.363 As a reminder, on today's call, the company will be making forward-looking statements 00:01:11.363 -- 00:01:15.886 regarding regulatory and product development and commercialization plans, as well as 00:01:15.886 -- 00:01:18.007 research activities. 00:01:18.007 -- 00:01:21.188 These statements are subject to risks and uncertainties that may cause actual res...